Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

125.76 +0.74 (+0.59%)
Streaming Delayed Price Updated: 12:45 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
67 68 Next >
News headline image
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy? ↗
Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week... 
Via Talk Markets
News headline image
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why ↗
Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered... 
Via Benzinga
News headline image
Why Is Xilio Therapeutics (XLO) Stock up 168% Today? ↗
Xilio Therapeutics stock is heading higher on Thursday with heavy trading of XLO shares after announcing a deal with Gilead. 
Via InvestorPlace
News headline image
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Analyzing NASDAQ:GILD's Dividend Potential. ↗
Is GILEAD SCIENCES INC (NASDAQ:GILD) a Good Fit for Dividend Investing? 
Via Chartmill
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today ↗
 
Via Benzinga
News headline image
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
Via GlobeNewswire
News headline image
7 Value Stocks to Buy at a 52-Week Low in March ↗
These seven value stocks to buy all trade at low valuations, and have the potential to make big recoveries. 
Via InvestorPlace
News headline image
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields ↗
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
News headline image
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
News headline image
Balancing Dividends and Fundamentals: The Case of NASDAQ:GILD. ↗
Exploring GILEAD SCIENCES INC (NASDAQ:GILD)'s dividend characteristics. 
Via Chartmill
News headline image
2 Top Dividend Stocks to Buy Hand Over Fist ↗
Every company faces headwinds eventually. The top ones know how to bounce back. 
Via The Motley Fool
News headline image
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy? ↗
Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week... 
Via Talk Markets
News headline image
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production ↗
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
Via Benzinga
News headline image
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Dividend Stocks to Buy Hand Over Fist in March ↗
Income investors might want to load up on these great dividend stocks. 
Via The Motley Fool
News headline image
The AI Race Gets Litigious ↗
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer ↗
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... 
Via Benzinga
News headline image
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
News headline image
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy ↗
Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed. 
Via Benzinga
News headline image
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers ↗
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal... 
Via Benzinga
News headline image
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound ↗
While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities. 
Via InvestorPlace
News headline image
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges ↗
The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management. 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.